Brazil achieves milestone in eliminating lymphatic filariasis

The World Health Organization (WHO) congratulates Brazil for having eliminated lymphatic filariasis as a public health problem.

Risk Adjusted Net Present Value: What is the current valuation of Sandoz Group’s Ustekinumab Biosimilar

The revenue for Ustekinumab Biosimilar is expected to reach an annual total of $285 mn by 2028 globally based off GlobalData’s Revenue Model. The drug’s

November 4, 2023

Roivant’s dealmaker lands $81M cash bonus following drug sale to Roche

One of the best pharma deals in recent history has now led to one of the industry’s biggest-ever executive paydays. Roivant awarded its top dealmaker

July 30, 2024

GLP-1 Drugs Tied to Reduced Risk of Dangerous Blood Clots

SAN DIEGO — Type 2 diabetes patients may have a lower risk of venous thromboembolism (VTE) when treated with a GLP-1 receptor agonist, regardless of

December 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.